Replimune Group Inc. (REPL)
NASDAQ: REPL
· Real-Time Price · USD
7.68
-0.08 (-1.09%)
At close: May 09, 2025, 3:59 PM
7.60
-1.04%
After-hours: May 09, 2025, 05:36 PM EDT
-1.09% (1D)
| Bid | 5.94 |
| Market Cap | 591.47M |
| Revenue (ttm) | 4.04M |
| Net Income (ttm) | -228.24M |
| EPS (ttm) | -3.07 |
| PE Ratio (ttm) | -2.5 |
| Forward PE | -2.61 |
| Analyst | Buy |
| Ask | 9.26 |
| Volume | 1,170,630 |
| Avg. Volume (20D) | 854,985 |
| Open | 7.77 |
| Previous Close | 7.76 |
| Day's Range | 7.65 - 8.52 |
| 52-Week Range | 4.92 - 17.00 |
| Beta | 0.68 |
About REPL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol REPL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for REPL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
+9.87%
Replimune Group shares are trading higher after HC...
Unlock content with
Pro Subscription
3 months ago
+16.86%
Replimune Group shares are trading higher after the company announced the FDA has accepted the biologics license application for RP1 in combination with nivolumab for patients with advanced melanoma
